Pinealon

Pinealon is Glu-Asp-Arg. Fluorescent-label studies from Khavinson's group show the peptide entering cultured neurons and reaching the nucleus, which is the core structural argument for the whole Cytogen concept. In rodent models of prenatal hypoxia and in cultured cerebellar and cortical neurons, Pinealon is reported to reduce reactive oxygen species, limit caspase-3-mediated apoptosis and preserve learning performance. It is also described as normalising serotonin and melatonin-related signalling, which is where the sleep claims come from. Every one of these findings originates within the same research programme; none has been independently replicated.

Targets: Neurons, Caspase-3 apoptotic pathway, Antioxidant gene expression, Serotonin signalling

• · 1-2 mg/day from a 20 mg vial is the standard vial-market protocol, not a validated dose.
• · The capsule form is how most of Eastern Europe uses it. Oral bioavailability of an intact tripeptide is unproven.

Work out your exact syringe units →

• commonInjection-site irritation— Transient.
• uncommonMild headache in the first days— Commonly reported anecdotally; usually settles.
• uncommonSleep disturbance if dosed late— Some users find it mildly alerting - dose in the morning if this happens.

• Pregnancy and breastfeeding - no data.
• Active brain malignancy - a gene-de-repressing peptide aimed at neural tissue is a bad theoretical fit.

• synergycortagen — The two brain-directed Cytogens are routinely run together in Russian protocols; the pairing is convention, not demonstrated synergy.
• redundantcerluten — Cerluten is the brain Cytomax extract covering the same claimed ground.
• synergysemax — Frequently stacked in nootropic protocols; Semax has far stronger clinical evidence and is doing most of the work.

• · Use a fixed cognitive self-test or a reaction-time app before and after a course rather than trusting recall.
• · No bloodwork is established.

Not approved for human use in the US, UK or EU; sold as a research chemical or as a supplement capsule in Russia and Eastern Europe.

• Khavinson et al., neuroprotective effects of the tripeptide EDR in models of hypoxia (Bulletin of Experimental Biology and Medicine) (preclinical)
• Khavinson, Linkova & Tarnovskaya, short peptides regulate gene expression (preclinical)

Pinealon has the most physically detailed mechanistic file in the Cytogen series, and it is worth separating the parts that are solid from the parts that are inference. Solid: Glu-Asp-Arg reaches the nucleus. Fedoreyeva and Vanyushin labelled it with fluorescein and watched it enter HeLa cell cytoplasm, nucleus and nucleolus, and showed that it binds deoxyribooligonucleotides with sequence preference - EDR favours CNG-containing sequences, the exact motifs that are targets for cytosine methylation in eukaryotes, and shows a preference for CAG blocks. A 2019 molecular dynamics study in the Journal of Physical Chemistry B went further and modelled how mono- and divalent ions mediate the Glu-Asp-Arg-DNA interaction, which is unusually rigorous physical chemistry for this field and was published in a mainstream American Chemical Society journal. The arginine is doing the heavy lifting there: it is the residue with the guanidinium group that makes the major-groove contact plausible. Inference: everything about neurons. The functional claims come from rodent work in which EDR reduced caspase-3 activity and modulated cytokines in aged rat brain, preserved learning under prenatal hypoxia, and lowered reactive oxygen species in cultured cerebellar and cortical neurons. Khavinson's group also reported that short peptides including EDR raise serotonin expression in brain cortex cells, which is where the sleep and mood claims originate. What is missing is the step in between: nobody has shown that a peripherally injected dose of EDR crosses the blood-brain barrier in a measurable quantity. A charged tripeptide is not an obvious BBB penetrant. The rodent behavioural results are real observations; the mechanism connecting a subcutaneous injection to a cortical neuron nucleus is assumed.

The barrier problem is the thing to keep in front of you: nobody has shown that a peripherally injected charged tripeptide reaches brain tissue in a person. Every neuronal result in the file is either a dish or a rodent, and rodent BBB permeability is not a safe guide. The second failure is the substitution failure - people use nootropic peptides instead of investigating cognitive symptoms that have common, cheap, treatable causes. Get the B12, the thyroid, the ferritin and the sleep apnoea assessed before you conclude your problem is age-silenced neuronal genes. Third, some users find it mildly alerting and dose it at night, then blame the compound for poor sleep; move it to morning. Fourth, intranasal dosing is popular on the research market and has zero supporting data - nasal mucosal absorption of this peptide has never been characterised, and inventing a route because it sounds like it should bypass the BBB is not a plan.

• Double-stranded DNA, CNG- and CAG-containing sequences — Characterised by Stern-Volmer fluorescence-quenching constants showing sequence and methylation-state discrimination; no molar Kd published

  Proposed sequence-selective major-groove binding at methylation-target motifs, de-repressing neuronal genes. The 2019 molecular dynamics work models the ion-mediated geometry of this interaction.

• Caspase-3 apoptotic pathway in neurons

  Reduced caspase-3 activity in aged rat brain and in neuronal cultures under oxidative and hypoxic stress - the anti-apoptotic claim, and the most reproducible functional finding the peptide has.

• Reactive oxygen species in cerebellar and cortical neuron culture

  Reduced ROS accumulation, framed as the antioxidant neuroprotection claim.

• Serotonin expression in cerebral cortex cells

  Increased serotonin expression in cortical cell culture after short-peptide exposure. This is the entire evidentiary basis for the mood and sleep claims and it is a dish, not a person.

• No identified receptor — None published

  No cell-surface or nuclear receptor has been identified for EDR.

Days one to three: most people report nothing. A minority describe mild alertness within an hour or two of a morning dose, which is unverifiable and easily expectation. A mild headache in the first two or three days is the commonest anecdotal complaint and usually settles. Days seven to fourteen: if any cognitive change is going to be reported, this is the window described in user accounts. Test with a fixed reaction-time or n-back task run at the same time of day, before and after, because subjective cognitive self-assessment is close to worthless. End of course to four weeks after: the rodent neuroprotection results were measured after dosing periods, so if anything persists this is where. Beyond that: nothing established.

Pinealon plus Cortagen is the conventional brain pairing - neuron peptide plus cortex peptide - and it is convention, not demonstrated synergy; no combination study exists. Pinealon plus Cerluten is duplication, since Cerluten is the brain extract from the same lineage. The stack worth being honest about is Pinealon plus Semax: Semax has Russian registration, human stroke and cognitive trial data, and a defined melanocortin-related mechanism. In that pairing Semax is doing the work and Pinealon is along for the ride, and if you run them together and something improves you will credit the wrong compound. If you want to know whether Pinealon does anything, run it alone with a fixed cognitive benchmark.

Against Semax: no contest on evidence. Semax is registered in Russia, has human trial data in ischaemic stroke and cognitive impairment, and a plausible melanocortin mechanism. Pinealon has cell culture, aged rodents and excellent physical chemistry on DNA binding. Against Cerebrolysin: Cerebrolysin is a porcine brain peptide preparation with multiple Western-indexed randomised trials in stroke and dementia, given intravenously at gram-scale doses. It is a different order of evidence. Against Cortagen: Cortagen has a concrete in vivo functional result - nerve conduction velocity in a sciatic nerve model - which Pinealon lacks, but Pinealon has better molecular characterisation. Against Epitalon: same family; Epitalon owns the telomerase story, Pinealon owns the neuronal one, and both rest on the same unverified premise that an injected short peptide reaches target-cell nuclei in a human.

$35–$120/month. One 20 mg vial covers a ten- to twenty-day course at 1-2 mg per day. Two to three courses a year. Indicative research-chemical pricing, not verified against vendor listings in this session.

• ?No human pharmacokinetic or pharmacodynamic data of any kind exists for this peptide.
• ?Blood-brain barrier penetration has never been measured. Every neurological claim depends on it and none of them demonstrate it.
• ?The serotonin result is cortical cell culture; no human neurotransmitter or mood measurement has been made.
• ?No human trial exists. The cognitive claims are entirely anecdotal at the human level.
• ?Intranasal dosing, which is widely used on the research market, has no absorption or safety data at all.
• ?The microgram-versus-milligram dosing gap between the source literature and the vial market applies here as it does across the class.
• ?There is no molar binding affinity for the DNA interaction, only relative fluorescence-quenching constants.
• ?Cost figures are indicative research-chemical estimates and were not verified against live vendor listings in this session.

• Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF, Biochemistry (Moscow), 2011 · PMID 22117547

  Names pinealon as Glu-Asp-Arg, shows it entering the nucleus and nucleolus, and reports its preference for CNG and CAG sequences. The single most important paper for this compound.

• Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction Silanteva IA, Komolkin AV, Morozova EA, et al., The Journal of Physical Chemistry B, 2019 · PMID 30762356

  Molecular dynamics of the EDR-DNA interaction in a mainstream ACS physical chemistry journal. This is the most rigorous non-Khavinson-institute physical work on any compound in the class.

• Short peptides stimulate serotonin expression in cells of brain cortex Khavinson VKh, Lin'kova NS, Tarnovskaya SI, Umnov RS, Elashkina EV, Durnova AO, Bulletin of Experimental Biology and Medicine, 2014 · PMID 24909721

  The origin of the mood and sleep claims. Cortical cell culture, not human data.

• Effects of short peptides on behavior and caspase-3 activity in aged rat brains Mendzheritskiĭ AM, Karantysh GV, Ivonina KO, et al., Advances in Gerontology, 2011 · PMID 21809624

  Behaviour plus a molecular apoptosis endpoint in aged rats - the closest thing Pinealon has to an in vivo functional result.

• Regulation of cytokines and caspase-3 activity in aging rat brains Mendzheritskiĭ AM, Karantysh GV, Ryzhak GA, et al., Advances in Gerontology, 2014 · PMID 25051764

  Follow-up linking the anti-apoptotic effect to cytokine modulation in the ageing brain.

• Biological activity of regulatory peptides in model experiments in vitro Kozina LS, Arutiunian AV, Stvolinskiĭ SL, et al., Advances in Gerontology, 2008 · PMID 18546826

  The free-radical and neuronal viability model work underlying the antioxidant claim.

• Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture Khavinson VKh, Linkova NS, Chalisova NI, et al., Bulletin of Experimental Biology and Medicine, 2011 · PMID 22803060

  Signalling-molecule expression in pineal organotypic culture, which is where the circadian framing for this peptide comes from.